Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Meenal Sinha(Premier Research Group), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center)
Cited by 11
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
|Cell|2023|410
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
|Prostate Cancer and Prostatic Diseases|2021|224
Predictors of responses to immune checkpoint blockade in advanced melanoma
|Nature Communications|2017|201